|
|
January 8, 2024
 In a pivotal development in 2022, the X-waiver requirement for prescribing medications, including Buprenorphine, for opioid use disorder (OUD) has been removed by the Mainstreaming Addiction Treatment (MAT) Act and the Medication Training and Expansion (MATE) Act. Practitioners with current DEA registration, including Schedule III authority, can now prescribe buprenorphine and other substance use disorder (SUD) medications, subject to state law.
Key Highlights
-
Increased Prescribing Authority: Removal of the X-waiver expands buprenorphine prescribing to nurse practitioners, physician assistants, and resident physicians.
-
Reducing Discrimination: This change aims to decrease discrimination against individuals with SUD in post-acute care settings such as nursing homes, rehabilitation centers, prisons, and jails.
-
Opportunity for Integrated Care: The elimination of the X-waiver presents an opportunity for family medicine and affiliated organizations to integrate SUD treatment into existing chronic disease care models.
Next Steps for MAT Providers
If you aspire to contribute as a MAT provider and be a champion for SUD treatment in your community, explore the attached resources for guidance.
Thank you for your prompt attention to this critical update. Your role as a MAT provider can make a substantial impact on the treatment landscape for SUD.
Resources
Was this email forwarded to you? Join our list to receive updates for healthcare providers!
|
|
|
|
